CRB-913 in Obesity
CRB-913 demonstrated a favorable safety profile with mean weight loss of up to 5% at 12 weeks with no plateau observed. These data support CRB-913’s potential to establish a new class of non-incretin obesity medicines. The data was selected for a late-breaking presentation at ObesityWeek® 2026
CRB-913 is a once-daily, highly peripherally restricted oral CB1 inverse agonist designed as a potential non-incretin approach to weight loss and long-term weight management.
Explore the Canyon-1 data including the press release, corporate presentation, KOL webcast, media coverage and upcoming scientific conferences.
Upcoming
Presentations and Events
CRB-913 at Obesity Week 2026
CANYON-1 data have been selected for a late-breaking presentation at ObesityWeek 2026, taking place November 14–17 in Washington, DC.
Visit our poster and meet the Corbus team to learn more about the study findings and discuss the potential of CRB-913 as an oral, non-incretin treatment for obesity.
Poster: Efficacy, Safety, and Tolerability of CRB-913 in the Phase 1b CANYON-1 Study
Sunday, November 15 | 2:30–3:30 PM ET
Gaylord National Resort & Convention Center
Exhibit Hall BCD, Washington, DC
Featured Coverage and Interviews
Explore recent coverage and conversations about CANYON-1, CRB-913 and the evolving treatment landscape in obesity.
Featured Article
Trial breakthrough for weight-loss drug with fewer side effects
Financial Times
Ahead of CANYON-1: CRB-913 and its potential in obesity
Ahead of the CANYON-1 topline data readout, Corbus CEO Yuval Cohen discussed CRB-913 and its potential in obesity on the Molecules and Minerals podcast.